Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 6 ans
Étude GEP-NEC : étude de phase 2 visant à évaluer l’efficacité et la sécurité d’emploi du PDR001 chez des patients ayant des tumeurs neuroendocrines non-fonctionnelles avancées ou métastatiques bien différentiées du pancréas, du tractus gastrointestinal ou du thorax ou un carcinome neuroendocrine gastroenteropancréatique peu différentié qui a progressé sous un traitement antérieur.
Les tumeurs neuroendocrines prennent naissance dans les cellules du système neuroendocrinien qui sont dispersées dans tout le corps. Ces cellules reçoivent des signaux du système nerveux et fabriquent...
Country
France
organs
Système endocrinien - autres
,
Pancréas
,
Estomac
,
Intestin
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg everolimus tablets suspended in 30 mL of water to healthy subjects
To evaluate the bioavailability of: 5 x 1 mg everolimus intact tables, and 5 x 1 mg everolimus tablets suspended in 30 mL of water
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Phase II study for the treatment of abdominal aortic aneurysm
To assess the effect of ACZ885 on AAA size and growth rate as measured with ultrasound at 12 months.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
NOVARTIS CAMN107G2301 : Essai de phase 3 randomisé comparant l’efficacité et la tolérance du nilotinib à celle de l’imatinib, chez des patients ayant une tumeur stromale gastro-intestinale non opérable ou métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A randomized, open label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumor...
Country
France
organs
Tumeurs stromales digestives (GIST)
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A study to evaluate the safety and tolerability of the combination of an antidepressive therapy with oral fingolimod in the treatment of relapsing remitting multiple sclerosis patients with mild to moderate depression
To evaluate the safety and tolerability profile of the combination therapy of an antidepressant type SSRI or SNRI with oral fingolimod with respect to adverse events and laboratory parameters
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
NOVARTIS CLBH589H2101 : essai de phase 1, en escalade de dose, visant à déterminer la dose maximale tolérée du panobinostat (LBH589) associé à du 5 -azacitidine, chez des patients ayant un syndrome myélodysplasique, une leucémle myélo-monocytaire chronique ou une leucémie aiguë myéloïde. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase I/b, open-label, multi-center, dose-escalation study of oral panobinostat (LBH589) administered with 5-azacitidine (Vidaza®) in adult patients with myelodysplastic syndromes (MDS), chronic mye...
Country
France
organs
Syndromes myélodysplasiques (SMD)
,
Leucémies chroniques
,
Leucémies aiguës
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Sponsored by Novartis Pharmaceuticals Corporation ( http://click.atdmt.com/GTO/go/thbmbnov00700895gto/direct/01 /)
Update Il y a 5 ans
IBS-C Study A2306
Not provided at time of registration
Country
United States
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An eight-week, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of the combination of aliskiren / HCTZ (300/12.5 mg and 300/25 mg) in comparison with aliskiren 300 mg in patients with essential hypertension not adequately responsive to aliskiren 300 mg monotherapy
Demonstrate the efficacy of the combination therapy of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to a 4-week treatment o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis
Part 1: To evaluate the efficacy of AIN457 at 6 weeks based on the proportion of patients achieving an ASAS20 response Part 2: To evaluate the efficacy of lower doses of AIN457 at 6 weeks based on the...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatment in patients with hormone-refractory prostate cancer
To investigate the effect of a treatment with Imatinib mesylate (Glivec®), Pioglitazone (Actos®), Dexamethasone (Fortecortin®) and Etoricoxib (Arcoxia®) in combination with metronomic chemotherapy (Tr...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next